Ph.D., Vice President, Biomaker Sciences, Gilead Sciences
Scott Patterson, PhD, is Vice President, Biomarker Sciences in the R&D organization at Gilead Sciences, Inc, where he is responsible for development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas. Previously, he was Executive Director, Medical Sciences at Amgen, Inc, where he established the company’s biomarker strategy and led the In Vitro Diagnostics Group from its inception. Prior to Amgen, Dr. Patterson was Vice President, Proteomics at Celera Genomics. Earlier in his career, he held research appointments at Amgen and at Cold Spring Harbor Laboratory, New York. Dr. Patterson received BSc and PhD degrees from The University of Queensland in Australia.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: This session will cover how precision medicine overlays into the issue of cost-effective clinical care. The cost of medical care remains a timely topic. Different stakeholders (payers, PHARMA, the government) will engage in a lively discussion on issues related to cost of care, political aspects of care delivery, and how precision medicine applies and can be defined as getting the “right therapy to the right patient at the right time….at the right price.”